A5059727217- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Hormonal Regulation and Hypertension
- Cancer Treatment and Pharmacology
- Electroconvulsive Therapy Studies
- Advanced Breast Cancer Therapies
- Cardiac pacing and defibrillation studies
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Cardiovascular Function and Risk Factors
- Bariatric Surgery and Outcomes
- Neurological disorders and treatments
- Heart Failure Treatment and Management
- Advanced MRI Techniques and Applications
- HER2/EGFR in Cancer Research
- Radiation Dose and Imaging
- Cancer-related Molecular Pathways
- Blood Pressure and Hypertension Studies
- Liver Disease Diagnosis and Treatment
- Cardiovascular Disease and Adiposity
- BRCA gene mutations in cancer
- Cardiac Structural Anomalies and Repair
- Breast Lesions and Carcinomas
- Antiplatelet Therapy and Cardiovascular Diseases
Universidade de São Paulo
2022-2024
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2023-2024
Instituto do Coração
2023
Universidade Estadual de Montes Claros
2023
Transcatheter edge-to-edge repair (TEER) has become an established treatment for primary and secondary mitral regurgitation (PMR SMR). The objective of this study was to compare the accuracy different risk scores predicting 1-year mortality composite endpoint and/or heart failure (HF) hospitalization after TEER.
1065 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are standard-of-care for patients hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/ HER2-) metastatic breast cancer (mBC). Yet, disease progression is common in these patients. In the absence of established guidelines optimal sequencing post-progression, we conducted a pooled analysis patient data to assess efficacy subsequent treatment options following on...
PURPOSE Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy (ET) are the standard of care in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (aBC). Yet, disease progression remains common. In absence established postprogression sequencing guidelines, we conducted a pooled analysis Kaplan-Meier (KM)–derived patient data to assess efficacy subsequent treatment options after on CDK4/6i therapy. METHODS...
Introduction: Atrial fibrillation (AF) is associated with an increased risk of impaired quality life, stroke, and mortality. Despite multiple studies, the optimal target for rate control in AF not definitively known. Methods: We performed a systematic review meta-analysis comparing effects strict (<80 bpm at rest) lenient strategy (<110 patients AF. The outcomes analyzed were all-cause mortality, cardiovascular (CV) death CV hospitalization. A subgroup analysis was also heart failure...
Introduction: Sacubitril-Valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) associated with a decreased risk of death and hospitalization for heart failure. However, its effects on atherosclerotic disease outcomes are not definitively known. Methods: We performed systematic review meta-analysis comparing the ARNI angiotensin-converting enzyme (ACEI) or blocker (ARB) acute coronary syndrome (ACS), myocardial infarction (MI), stroke, angina pectoris peripheral artery (PAD)....